EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD

Zarmina Javed iD, Mengke Du iD, Mary Rensel, Le H Hua, Carrie M Hersh, Justin R Abbatemarco, Devon S Conway, Daniel Ontaneda, Jeffrey A Cohen, Amy Kunchok iD

Annals of Clinical and Translational Neurology · 2025-10 · 12 (10) · 2152-2157

DOI: 10.1002/acn3.70160 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 22.08.2025. Verfasst von Zarmina Javed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Neuromyelitis Optica, Rituximab, Immunologic Factors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this multicenter retrospective cohort study of 135 people with aquaporin‐4 IgG+ neuromyelitis optica spectrum disorder (NMOSD), some of whom were exposed to multiple therapies, we evaluated the effectiveness and tolerability of rituximab ( n = 111) and novel monoclonal antibodies (nMAbs): eculizumab ( n = 9), inebilizumab ( n = 23), and satralizumab ( n = 14). Over a median follow‐up of 3.92 years, 21/111 rituximab‐treated patients relapsed. In contrast, relapse occurred in only 1/23 inebilizumab‐treated patients (median follow‐up 1.27 years), with no relapses observed in those receiving eculizumab or satralizumab. Twelve‐month relapse‐free probabilities were 92% (rituximab), 94% (inebilizumab), and 100% (eculizumab and satralizumab). Among those with available MRI data, 10/73 rituximab and 1/14 inebilizumab developed new lesions. There were no serious adverse events. These findings support nMAbs as effective and well‐tolerated first‐line therapies for NMOSD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromyelitis OpticaRituximabImmunologic FactorsAntibodies, Monoclonal, HumanizedHumansFemaleMaleMiddle AgedAdultRetrospective StudiesAgedAquaporin 4Follow-Up StudiesYoung Adult

Stichwörter der Autor:innen

NMOSDeffectivenessmonoclonal antibodiesrituximabtolerability

Substanzen

RituximabImmunologic FactorsAntibodies, Monoclonal, HumanizedeculizumabinebilizumabAquaporin 4

Autor:innen und Institutionen

  • Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Cleveland, Ohio, USA.
  • Lou Ruvo Center for Brain Health Las Vegas, Cleveland Clinic, Las Vegas, Nevada, USA.

ORCID-Profile: Zarmina Javed, Mengke Du, Amy Kunchok

Zitieren

APA

Javed, Z., Du, M., Rensel, M., Hua, L. H., Hersh, C. M., Abbatemarco, J. R., Conway, D. S., Ontaneda, D., Cohen, J. A., & Kunchok, A. (2025). Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD. Annals of Clinical and Translational Neurology, 12(10), 2152-2157. https://doi.org/10.1002/acn3.70160

Vancouver

Javed Z, Du M, Rensel M, Hua LH, Hersh CM, Abbatemarco JR, et al. Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD. Annals of Clinical and Translational Neurology. 2025;12(10):2152-2157. doi:10.1002/acn3.70160

BibTeX
@article{Javed2025,
  author = {Javed, Zarmina and Du, Mengke and Rensel, Mary and Hua, Le H and Hersh, Carrie M and Abbatemarco, Justin R and Conway, Devon S and Ontaneda, Daniel and Cohen, Jeffrey A and Kunchok, Amy},
  title = {Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {10},
  pages = {2152--2157},
  doi = {10.1002/acn3.70160}
}
Kostenlos starten →